Fingolimod suppresses bone resorption in female patients with multiple sclerosis
Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treat...
Saved in:
| Published in | Journal of neuroimmunology Vol. 298; pp. 24 - 31 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
15.09.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0165-5728 1872-8421 1872-8421 |
| DOI | 10.1016/j.jneuroim.2016.06.007 |
Cover
Loading…
| Abstract | Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.
[Display omitted]
•Fingolimod suppresses bone resorption in patients with MS.•Suppression of bone resorption by fingolimod is prominent in female MS patients.•Fingolimod may have a beneficial effect on bone mass loss in female MS patients. |
|---|---|
| AbstractList | Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N -telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. [Display omitted] •Fingolimod suppresses bone resorption in patients with MS.•Suppression of bone resorption by fingolimod is prominent in female MS patients.•Fingolimod may have a beneficial effect on bone mass loss in female MS patients. Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. |
| Author | Niino, Masaaki Shimohama, Shun Doi, Shizuki Minami, Naoya Fujiki, Naoto Amino, Itaru Nakamura, Masakazu Kanazawa, Ippei Miyazaki, Yusei Mizuno, Masanori Fukazawa, Toshiyuki Suzuki, Masako Hisahara, Shin Ochi, Ryutaro Akimoto, Sachiko Kikuchi, Seiji Takahashi, Eri Terayama, Yasuo |
| Author_xml | – sequence: 1 givenname: Yusei surname: Miyazaki fullname: Miyazaki, Yusei email: yuseimiyazaki@hok-mc.hosp.go.jp organization: Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 2 givenname: Masaaki surname: Niino fullname: Niino, Masaaki organization: Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 3 givenname: Ippei surname: Kanazawa fullname: Kanazawa, Ippei organization: Department of Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo 693-8501, Japan – sequence: 4 givenname: Masako surname: Suzuki fullname: Suzuki, Masako organization: Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan – sequence: 5 givenname: Masanori surname: Mizuno fullname: Mizuno, Masanori organization: Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan – sequence: 6 givenname: Shin surname: Hisahara fullname: Hisahara, Shin organization: Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo 060-8556, Japan – sequence: 7 givenname: Toshiyuki surname: Fukazawa fullname: Fukazawa, Toshiyuki organization: Sapporo Neurology Clinic, 2-17 Kita-21-jo Higashi-21-chome, Higashi-ku, Sapporo 065-0021, Japan – sequence: 8 givenname: Eri surname: Takahashi fullname: Takahashi, Eri organization: Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 9 givenname: Itaru surname: Amino fullname: Amino, Itaru organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 10 givenname: Ryutaro surname: Ochi fullname: Ochi, Ryutaro organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 11 givenname: Masakazu surname: Nakamura fullname: Nakamura, Masakazu organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 12 givenname: Sachiko surname: Akimoto fullname: Akimoto, Sachiko organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 13 givenname: Naoya surname: Minami fullname: Minami, Naoya organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 14 givenname: Naoto surname: Fujiki fullname: Fujiki, Naoto organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 15 givenname: Shizuki surname: Doi fullname: Doi, Shizuki organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan – sequence: 16 givenname: Shun surname: Shimohama fullname: Shimohama, Shun organization: Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo 060-8556, Japan – sequence: 17 givenname: Yasuo surname: Terayama fullname: Terayama, Yasuo organization: Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan – sequence: 18 givenname: Seiji surname: Kikuchi fullname: Kikuchi, Seiji organization: Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo 063-0005, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27609272$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1v1TAQtFARfS38hSpHLnn4I44dCSFQRQGpEkjA2XKcDTg4drCdov57HF7fpQdaaSV77ZlZe2fP0IkPHhC6IHhPMGlfTfvJwxqDnfe05HtcAosnaEekoLVsKDlBu3LBay6oPEVnKU0YE86a7hk6paLFHRV0h75cWf8jODuHoUrrskRICVLVl2pV2Ye4ZBt8ZX01wqwdVIvOFnxO1R-bf1bz6rJdynEyDmJINj1HT0ftEry4W8_R96v33y4_1tefP3y6fHddG05IrkfcYtNgSugomKGC8YFhMQAemB5BNEZI2jaScslpT0YNdOz6UYKh0HeCYnaOXh50lxh-r5Cymm0y4Jz2ENakiKSiI7zh9BFQIhmT-J_qxR107WcY1BLtrOOtOjasAF4fAKb8NkUYlbFZbz3KUVunCFabP2pSR3_U5o_CJbAo9PYe_VjhQeLbAxFKT28sRJVM8cHAYCOYrIZgH5Z4c0_COOut0e4X3EKawhp9cUwRlajC6us2PdvwkJZhwrrm_wKPecFf-AfZFg |
| CitedBy_id | crossref_primary_10_1016_j_bone_2019_115087 crossref_primary_10_1111_jcmm_15155 crossref_primary_10_3233_NIB_170126 crossref_primary_10_1016_j_msard_2024_105773 crossref_primary_10_1074_jbc_RA120_013573 crossref_primary_10_1038_s41413_022_00205_0 crossref_primary_10_1016_j_pharmthera_2019_107429 crossref_primary_10_1016_j_msard_2023_104726 |
| Cites_doi | 10.1212/WNL.0b013e31820db341 10.1212/WNL.0b013e3182242d34 10.1038/sj.emboj.7601430 10.1007/s002239900309 10.1007/s00223-003-0155-9 10.1371/journal.pone.0045703 10.1074/jbc.C200176200 10.1191/1352458503ms966oa 10.1016/j.clim.2014.02.001 10.1212/WNL.44.9.1687 10.1016/j.clim.2011.05.005 10.1191/1352458504ms993oa 10.1210/jc.2012-1044 10.1054/plef.1999.0100 10.1084/jem.20101474 10.1002/jbmr.2047 10.1096/fj.03-0910fje 10.1007/s40263-014-0173-3 10.1177/1352458510368985 10.1172/JCI76369 10.1126/science.1070238 10.1038/nature07713 10.1212/WNL.0b013e3181beece8 10.1073/pnas.1014154108 10.1210/jc.2012-2346 10.1002/jbmr.1475 10.1016/j.jneuroim.2012.12.005 10.1038/ncomms6215 10.1212/WNL.51.4.1161 10.1016/j.bbrc.2012.05.130 10.1177/1352458506070605 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier B.V. Elsevier B.V. Copyright © 2016 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2016 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2016 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 7TK H94 |
| DOI | 10.1016/j.jneuroim.2016.06.007 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Neurosciences Abstracts Immunology Abstracts |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1872-8421 |
| EndPage | 31 |
| ExternalDocumentID | 27609272 10_1016_j_jneuroim_2016_06_007 S0165572816301394 1_s2_0_S0165572816301394 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4CK 4G. 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABTEW ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGUBO AGWIK AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HMO HMQ IHE J1W KOM L7B LUGTX LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSI SSN SSZ T5K UNMZH Z5R ~G- .GJ 29L 53G AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO AFCTW AFJKZ AFKWA AHHHB AJOXV AKRLJ AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HDW HMG HMK HVGLF HZ~ R2- RIG SAE SEW SIN SNS WUQ XJT ZGI AADPK AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR ZA5 AAYXX AGQPQ AGRNS AIGII CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 7TK H94 |
| ID | FETCH-LOGICAL-c511t-f060c40212f73c2735d307de0d3afe74c78264825852b1fae2f9bf8ec2eb97203 |
| IEDL.DBID | .~1 |
| ISSN | 0165-5728 1872-8421 |
| IngestDate | Fri Jul 11 03:24:28 EDT 2025 Thu Jul 10 17:34:40 EDT 2025 Mon Jul 21 06:00:02 EDT 2025 Thu Apr 24 23:01:53 EDT 2025 Tue Jul 01 01:53:30 EDT 2025 Fri Feb 23 02:27:46 EST 2024 Tue Feb 25 19:59:02 EST 2025 Tue Aug 26 17:33:11 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | RANKL Multiple sclerosis Fingolimod MS S1PR P1NP uNTX ECLIA IFN Bone resorption BAP Osteoporosis S1P TRACP Sphingosine-1-phosphate Osteoclasts HC EIA UT BMI EDSS sphingosine-1-phosphate receptor electro-chemiluminescence immunoassay expanded disability status scale bone-specific alkaline phosphatase receptor activator of nuclear factor kappa-B ligand healthy controls untreated multiple sclerosis body mass index tartrate-resistant acid phosphatase interferon enzyme immunoassay urinary type I collagen cross-linked N-telopeptide procollagen type 1 amino-terminal propeptide sphingosine-1-phosphate |
| Language | English |
| License | Copyright © 2016 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c511t-f060c40212f73c2735d307de0d3afe74c78264825852b1fae2f9bf8ec2eb97203 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 27609272 |
| PQID | 1818338020 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1827915452 proquest_miscellaneous_1818338020 pubmed_primary_27609272 crossref_citationtrail_10_1016_j_jneuroim_2016_06_007 crossref_primary_10_1016_j_jneuroim_2016_06_007 elsevier_sciencedirect_doi_10_1016_j_jneuroim_2016_06_007 elsevier_clinicalkeyesjournals_1_s2_0_S0165572816301394 elsevier_clinicalkey_doi_10_1016_j_jneuroim_2016_06_007 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-09-15 |
| PublicationDateYYYYMMDD | 2016-09-15 |
| PublicationDate_xml | – month: 09 year: 2016 text: 2016-09-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of neuroimmunology |
| PublicationTitleAlternate | J Neuroimmunol |
| PublicationYear | 2016 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Carpio, Stepahn, Kamer, Dziak (bb0010) 1999; 61 Marrie, Cutter, Tyry, Vollmer (bb0090) 2009; 73 Mandala, Hajdu, Bergstrom, Quackenbush, Xie, Milligan, Thornton, Shei, Card, Keohane, Rosenbach, Hale, Lynch, Rupprecht, Parsons, Rosen (bb0085) 2002; 296 Moen, Celius, Sandvik, Nordsletten, Eriksen, Holmøy (bb0115) 2011; 77 Nieves, Cosman, Herbert, Shen, Lindsay (bb0120) 1994; 44 Lee, Lee, Lee, Kim, Lim, Cho, Kim, Koh, Kim (bb0080) 2012; 97 Eastell, Nagase, Small, Boonen, Spector, Ohyama, Kuwayama, Deacon (bb0025) 2014; 29 Formica, Cosman, Nieves, Herbert, Lindsay (bb0030) 1997; 61 Gräler, Goetzl (bb0035) 2004; 18 Mehling, Johnson, Antel, Kappos, Bar-Or (bb0100) 2011; 76 Gupta, Ahsan, Mahfooz, Abdelhamid, Ramanathan, Weinstock-Guttman (bb0045) 2014; 28 Masarachia, Pennypacker, Pickarski, Scott, Wesolowski, Smith, Samadfam, Goetzmann, Scott, Kimmel, Duong (bb0095) 2012; 27 Weinstock-Guttman, Hong, Santos, Tamaño-Blanco, Badgett, Patrick, Baier, Feichter, Gallagher, Garg, Ramanathan (bb0155) 2006; 12 Tüzün, Altıntaş, Karacan, Tangürek, Saip, Siva (bb0145) 2003; 9 Grey, Xu, Hill, Watson, Callon, Reid, Cornish (bb0040) 2004; 74 Ishii, Egen, Klauschen, Meier-Schellersheim, Saeki, Vacher, Proia, Germain (bb0060) 2009; 458 Sato, Iwasaki, Kitano, Tsunemi, Sano (bb0140) 2012; 423 Hearn, Silber (bb0050) 2010; 16 Kim, Koh, Lee, Lee, Lee, Lim, Cho, Kim, Kim, Kim, Kim (bb0075) 2012; 97 Moen, Celius, Sandvik, Brustad, Nordsletten, Eriksen, Holmøy (bb0110) 2012; 7 Ishii, Kikuta, Shimazu, Meier-Schellersheim, Germain (bb0065) 2010; 207 Miyazaki, Niino, Fukazawa, Takahashi, Nonaka, Amino, Tashiro, Minami, Fujiki, Doi, Kikuchi (bb0105) 2014; 151 Noda, Takeuchi, Mizuno, Suzumura (bb0125) 2013; 256 Weinstock-Guttman, Gallagher, Baier, Green, Feichter, Patrick, Miller, Wrest, Ramanathan (bb0150) 2004; 10 Choi, Gardell, Herr, Rivera, Lee, Noguchi, Teo, Yung, Lu, Kennedy, Chun (bb0015) 2011; 108 Proia, Hla (bb0130) 2015; 125 Brinkmann, Davis, Heise, Albert, Cottens, Hof, Bruns, Prieschl, Baumruker, Hiestand, Foster, Zollinger, Lynch (bb0005) 2002; 277 Ryu, Kim, Chang, Huang, Banno, Kim (bb0135) 2006; 25 Cosman, Nieves, Komar, Ferrer, Herbert, Formica, Shen, Lindsay (bb0020) 1998; 51 Keller, Catala-Lehnen, Huebner, Jeschke, Heckt, Lueth, Krause, Koehne, Albers, Schulze, Schilling, Haberland, Denninger, Neven, Hermans-Borgmeyer, Streichert, Breer, Barvencik, Levkau, Rathkolb, Wolf, Calzada-Wack, Neff, Gailus-Durner, Fuchs, de Angelis, Klutmann, Tsourdi, Hofbauer, Kleuser, Chun, Schinke, Amling (bb0070) 2014; 5 Ingwersen, Aktas, Kuery, Kieseier, Boyko, Hartung (bb0055) 2012; 142 Carpio (10.1016/j.jneuroim.2016.06.007_bb0010) 1999; 61 Eastell (10.1016/j.jneuroim.2016.06.007_bb0025) 2014; 29 Formica (10.1016/j.jneuroim.2016.06.007_bb0030) 1997; 61 Mandala (10.1016/j.jneuroim.2016.06.007_bb0085) 2002; 296 Hearn (10.1016/j.jneuroim.2016.06.007_bb0050) 2010; 16 Masarachia (10.1016/j.jneuroim.2016.06.007_bb0095) 2012; 27 Sato (10.1016/j.jneuroim.2016.06.007_bb0140) 2012; 423 Tüzün (10.1016/j.jneuroim.2016.06.007_bb0145) 2003; 9 Lee (10.1016/j.jneuroim.2016.06.007_bb0080) 2012; 97 Proia (10.1016/j.jneuroim.2016.06.007_bb0130) 2015; 125 Ryu (10.1016/j.jneuroim.2016.06.007_bb0135) 2006; 25 Gräler (10.1016/j.jneuroim.2016.06.007_bb0035) 2004; 18 Ishii (10.1016/j.jneuroim.2016.06.007_bb0060) 2009; 458 Weinstock-Guttman (10.1016/j.jneuroim.2016.06.007_bb0155) 2006; 12 Grey (10.1016/j.jneuroim.2016.06.007_bb0040) 2004; 74 Mehling (10.1016/j.jneuroim.2016.06.007_bb0100) 2011; 76 Nieves (10.1016/j.jneuroim.2016.06.007_bb0120) 1994; 44 Noda (10.1016/j.jneuroim.2016.06.007_bb0125) 2013; 256 Ingwersen (10.1016/j.jneuroim.2016.06.007_bb0055) 2012; 142 Marrie (10.1016/j.jneuroim.2016.06.007_bb0090) 2009; 73 Moen (10.1016/j.jneuroim.2016.06.007_bb0110) 2012; 7 Keller (10.1016/j.jneuroim.2016.06.007_bb0070) 2014; 5 Weinstock-Guttman (10.1016/j.jneuroim.2016.06.007_bb0150) 2004; 10 Cosman (10.1016/j.jneuroim.2016.06.007_bb0020) 1998; 51 Miyazaki (10.1016/j.jneuroim.2016.06.007_bb0105) 2014; 151 Brinkmann (10.1016/j.jneuroim.2016.06.007_bb0005) 2002; 277 Kim (10.1016/j.jneuroim.2016.06.007_bb0075) 2012; 97 Ishii (10.1016/j.jneuroim.2016.06.007_bb0065) 2010; 207 Gupta (10.1016/j.jneuroim.2016.06.007_bb0045) 2014; 28 Choi (10.1016/j.jneuroim.2016.06.007_bb0015) 2011; 108 Moen (10.1016/j.jneuroim.2016.06.007_bb0115) 2011; 77 |
| References_xml | – volume: 12 start-page: 541 year: 2006 end-page: 550 ident: bb0155 article-title: Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients publication-title: Mult. Scler. – volume: 207 start-page: 2793 year: 2010 end-page: 2798 ident: bb0065 article-title: Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo publication-title: J. Exp. Med. – volume: 125 start-page: 1379 year: 2015 end-page: 1387 ident: bb0130 article-title: Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy publication-title: J. Clin. Invest. – volume: 10 start-page: 170 year: 2004 end-page: 175 ident: bb0150 article-title: Risk of bone loss in men with multiple sclerosis publication-title: Mult. Scler. – volume: 76 start-page: S20 year: 2011 end-page: S27 ident: bb0100 article-title: Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis publication-title: Neurology – volume: 25 start-page: 5840 year: 2006 end-page: 5851 ident: bb0135 article-title: Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling publication-title: EMBO J. – volume: 277 start-page: 21453 year: 2002 end-page: 21457 ident: bb0005 article-title: The immune modulator FTY720 targets sphingosine 1-phosphate receptors publication-title: J. Biol. Chem. – volume: 458 start-page: 524 year: 2009 end-page: 528 ident: bb0060 article-title: Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis publication-title: Nature – volume: 61 start-page: 129 year: 1997 end-page: 133 ident: bb0030 article-title: Reduced bone mass and fat- free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use publication-title: Calcif. Tissue Int. – volume: 423 start-page: 200 year: 2012 end-page: 205 ident: bb0140 article-title: Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation publication-title: Biochem. Biophys. Res. Commun. – volume: 18 start-page: 551 year: 2004 end-page: 553 ident: bb0035 article-title: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors publication-title: FASEB J. – volume: 73 start-page: 1394 year: 2009 end-page: 1398 ident: bb0090 article-title: A cross-sectional study of bone health in multiple sclerosis publication-title: Neurology – volume: 7 year: 2012 ident: bb0110 article-title: Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study publication-title: PLoS One – volume: 296 start-page: 346 year: 2002 end-page: 349 ident: bb0085 article-title: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists publication-title: Science – volume: 9 start-page: 600 year: 2003 end-page: 604 ident: bb0145 article-title: Bone status in multiple sclerosis: beyond corticosteroids publication-title: Mult. Scler. – volume: 28 start-page: 731 year: 2014 end-page: 742 ident: bb0045 article-title: Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions publication-title: CNS Drugs – volume: 142 start-page: 15 year: 2012 end-page: 24 ident: bb0055 article-title: Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy publication-title: Clin. Immunol. – volume: 44 start-page: 1687 year: 1994 end-page: 1692 ident: bb0120 article-title: High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis publication-title: Neurology – volume: 29 start-page: 458 year: 2014 end-page: 466 ident: bb0025 article-title: Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study publication-title: J. Bone Miner. Res. – volume: 16 start-page: 1031 year: 2010 end-page: 1043 ident: bb0050 article-title: Osteoporosis in multiple sclerosis publication-title: Mult. Scler. – volume: 5 start-page: 1 year: 2014 end-page: 13 ident: bb0070 article-title: Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts publication-title: Nat. Commun. – volume: 108 start-page: 751 year: 2011 end-page: 756 ident: bb0015 article-title: FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine1-phosphate receptor 1 (S1P publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 27 start-page: 509 year: 2012 end-page: 523 ident: bb0095 article-title: Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys publication-title: J. Bone Miner. Res. – volume: 74 start-page: 542 year: 2004 end-page: 550 ident: bb0040 article-title: Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate publication-title: Calcif. Tissue Int. – volume: 97 start-page: E1421 year: 2012 end-page: E1428 ident: bb0080 article-title: Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans publication-title: J. Clin. Endocrinol. Metab. – volume: 51 start-page: 1161 year: 1998 end-page: 1165 ident: bb0020 article-title: Fracture history and bone loss in patients with MS publication-title: Neurology – volume: 61 start-page: 267 year: 1999 end-page: 273 ident: bb0010 article-title: Sphingolipids stimulate cell growth via MAP kinase activation in osteoblastic cells. publication-title: Prostaglandins Leukot. Essent. Fat. Acids – volume: 256 start-page: 13 year: 2013 end-page: 18 ident: bb0125 article-title: Fingolimod phosphate promotes the neuroprotective effects of microglia publication-title: J. Neuroimmunol. – volume: 77 start-page: 151 year: 2011 end-page: 157 ident: bb0115 article-title: Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome publication-title: Neurology – volume: 151 start-page: 127 year: 2014 end-page: 135 ident: bb0105 article-title: Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations publication-title: Clin. Immunol. – volume: 97 start-page: 3807 year: 2012 end-page: 3814 ident: bb0075 article-title: Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women publication-title: J. Clin. Endocrinol. Metab. – volume: 76 start-page: S20 year: 2011 ident: 10.1016/j.jneuroim.2016.06.007_bb0100 article-title: Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e31820db341 – volume: 77 start-page: 151 year: 2011 ident: 10.1016/j.jneuroim.2016.06.007_bb0115 article-title: Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome publication-title: Neurology doi: 10.1212/WNL.0b013e3182242d34 – volume: 25 start-page: 5840 year: 2006 ident: 10.1016/j.jneuroim.2016.06.007_bb0135 article-title: Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling publication-title: EMBO J. doi: 10.1038/sj.emboj.7601430 – volume: 61 start-page: 129 year: 1997 ident: 10.1016/j.jneuroim.2016.06.007_bb0030 article-title: Reduced bone mass and fat- free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use publication-title: Calcif. Tissue Int. doi: 10.1007/s002239900309 – volume: 74 start-page: 542 year: 2004 ident: 10.1016/j.jneuroim.2016.06.007_bb0040 article-title: Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate publication-title: Calcif. Tissue Int. doi: 10.1007/s00223-003-0155-9 – volume: 7 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0110 article-title: Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study publication-title: PLoS One doi: 10.1371/journal.pone.0045703 – volume: 277 start-page: 21453 year: 2002 ident: 10.1016/j.jneuroim.2016.06.007_bb0005 article-title: The immune modulator FTY720 targets sphingosine 1-phosphate receptors publication-title: J. Biol. Chem. doi: 10.1074/jbc.C200176200 – volume: 9 start-page: 600 year: 2003 ident: 10.1016/j.jneuroim.2016.06.007_bb0145 article-title: Bone status in multiple sclerosis: beyond corticosteroids publication-title: Mult. Scler. doi: 10.1191/1352458503ms966oa – volume: 151 start-page: 127 year: 2014 ident: 10.1016/j.jneuroim.2016.06.007_bb0105 article-title: Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations publication-title: Clin. Immunol. doi: 10.1016/j.clim.2014.02.001 – volume: 44 start-page: 1687 year: 1994 ident: 10.1016/j.jneuroim.2016.06.007_bb0120 article-title: High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.44.9.1687 – volume: 142 start-page: 15 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0055 article-title: Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy publication-title: Clin. Immunol. doi: 10.1016/j.clim.2011.05.005 – volume: 10 start-page: 170 year: 2004 ident: 10.1016/j.jneuroim.2016.06.007_bb0150 article-title: Risk of bone loss in men with multiple sclerosis publication-title: Mult. Scler. doi: 10.1191/1352458504ms993oa – volume: 97 start-page: E1421 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0080 article-title: Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2012-1044 – volume: 61 start-page: 267 year: 1999 ident: 10.1016/j.jneuroim.2016.06.007_bb0010 article-title: Sphingolipids stimulate cell growth via MAP kinase activation in osteoblastic cells. publication-title: Prostaglandins Leukot. Essent. Fat. Acids doi: 10.1054/plef.1999.0100 – volume: 207 start-page: 2793 year: 2010 ident: 10.1016/j.jneuroim.2016.06.007_bb0065 article-title: Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo publication-title: J. Exp. Med. doi: 10.1084/jem.20101474 – volume: 29 start-page: 458 year: 2014 ident: 10.1016/j.jneuroim.2016.06.007_bb0025 article-title: Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study publication-title: J. Bone Miner. Res. doi: 10.1002/jbmr.2047 – volume: 18 start-page: 551 year: 2004 ident: 10.1016/j.jneuroim.2016.06.007_bb0035 article-title: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors publication-title: FASEB J. doi: 10.1096/fj.03-0910fje – volume: 28 start-page: 731 year: 2014 ident: 10.1016/j.jneuroim.2016.06.007_bb0045 article-title: Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions publication-title: CNS Drugs doi: 10.1007/s40263-014-0173-3 – volume: 16 start-page: 1031 year: 2010 ident: 10.1016/j.jneuroim.2016.06.007_bb0050 article-title: Osteoporosis in multiple sclerosis publication-title: Mult. Scler. doi: 10.1177/1352458510368985 – volume: 125 start-page: 1379 year: 2015 ident: 10.1016/j.jneuroim.2016.06.007_bb0130 article-title: Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy publication-title: J. Clin. Invest. doi: 10.1172/JCI76369 – volume: 296 start-page: 346 year: 2002 ident: 10.1016/j.jneuroim.2016.06.007_bb0085 article-title: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists publication-title: Science doi: 10.1126/science.1070238 – volume: 458 start-page: 524 year: 2009 ident: 10.1016/j.jneuroim.2016.06.007_bb0060 article-title: Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis publication-title: Nature doi: 10.1038/nature07713 – volume: 73 start-page: 1394 year: 2009 ident: 10.1016/j.jneuroim.2016.06.007_bb0090 article-title: A cross-sectional study of bone health in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e3181beece8 – volume: 108 start-page: 751 year: 2011 ident: 10.1016/j.jneuroim.2016.06.007_bb0015 article-title: FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine1-phosphate receptor 1 (S1P1) modulation publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1014154108 – volume: 97 start-page: 3807 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0075 article-title: Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2012-2346 – volume: 27 start-page: 509 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0095 article-title: Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys publication-title: J. Bone Miner. Res. doi: 10.1002/jbmr.1475 – volume: 256 start-page: 13 year: 2013 ident: 10.1016/j.jneuroim.2016.06.007_bb0125 article-title: Fingolimod phosphate promotes the neuroprotective effects of microglia publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2012.12.005 – volume: 5 start-page: 1 year: 2014 ident: 10.1016/j.jneuroim.2016.06.007_bb0070 article-title: Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts publication-title: Nat. Commun. doi: 10.1038/ncomms6215 – volume: 51 start-page: 1161 year: 1998 ident: 10.1016/j.jneuroim.2016.06.007_bb0020 article-title: Fracture history and bone loss in patients with MS publication-title: Neurology doi: 10.1212/WNL.51.4.1161 – volume: 423 start-page: 200 year: 2012 ident: 10.1016/j.jneuroim.2016.06.007_bb0140 article-title: Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2012.05.130 – volume: 12 start-page: 541 year: 2006 ident: 10.1016/j.jneuroim.2016.06.007_bb0155 article-title: Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients publication-title: Mult. Scler. doi: 10.1177/1352458506070605 |
| SSID | ssj0015349 |
| Score | 2.236495 |
| Snippet | Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress... Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 24 |
| SubjectTerms | Adult Allergy and Immunology Bone resorption Bone Resorption - drug therapy Bone Resorption - etiology Collagen Type I - urine Disability Evaluation Female Fingolimod Fingolimod Hydrochloride - therapeutic use Humans Immunosuppressive Agents - therapeutic use Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple Sclerosis - urine Neurology Osteoclasts Osteoporosis Peptide Fragments - metabolism Peptides - urine Procollagen - metabolism Sex Characteristics Sphingosine-1-phosphate Tartrate-Resistant Acid Phosphatase - metabolism |
| Title | Fingolimod suppresses bone resorption in female patients with multiple sclerosis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165572816301394 https://www.clinicalkey.es/playcontent/1-s2.0-S0165572816301394 https://dx.doi.org/10.1016/j.jneuroim.2016.06.007 https://www.ncbi.nlm.nih.gov/pubmed/27609272 https://www.proquest.com/docview/1818338020 https://www.proquest.com/docview/1827915452 |
| Volume | 298 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhhdJLaZI-tk2CCqU3Z21ZD_u4hC7bLgmlbWhuQrLG4CXxLvHuIZf89o5keWnok_ZkW0hoGM_jkzQzIuSN4AClKVwiOciEs8wlNuMmAY6r59zkIjU-d_jsXM4u-IdLcblDTodcGB9WGW1_b9ODtY4t48jN8appxp99Io5QrEBE4XGMrwnKufJSfnK3DfNAhe4hMHZOfO_vsoQXJ4tQNLLxGemZDHU8_bWyP3dQvwKgwRFNn5DHEUHSSU_kHtmBdp8cTFpcPV_f0rc0xHSGzfJ98vAsHp0fkI9TdFLLK_w1jnabVYh_hY7aZQsU35c3wXbQpqU1XKPXoLHiakf9Vi0dAg9ph5Mi4U33lFxM3305nSXxOoWkQlS1TupUphX3Jd1rlVcIW4RDBXeQutzUoHiFYEFyXDEWgtmsNsDq0tYFVAxs6U9rn5HdFol6QWghUw7Y5qTJOHBhhcqMzZ0xEjILbkTEwENdxVrj_sqLKz0ElS30wHvtea9DdJ0akfF23KqvtvHHEWr4RXrIJUXrp9Eh_NtI6KISdzrTHdOp_kHQRqTcjrwnq3816-tBjjQqsj-dMS0sNzgbQqc8LxC-_64PU2W4Fn5EnvdCuOUTUzItmWIv_4O6V-SR__LxMJk4JLvrmw0cIeha2-OgVcfkweT9fHbun_NPX-ffAEMPLwo |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NTgJeprHB6GBgJMRbaOLYTvJYTas6tlZIbNLeLCe5SKm2tFraB_57zo5TgfgYgrfI8cnW-Xz3s-_DAO-lQMxMWgZKoAoEj8ogj4QJUNDpOTaxDI3NHZ7N1fRafLqRNztw2ufC2LBKr_s7ne60tW8ZeW6OVnU9-mITcWTCU0IUFseIR7Brq1PJAeyOzy-m860zQcYdCqb-gSX4LlF48XHh6kbWNik9Uq6Up31Z9tc26ncY1NmiyT7seRDJxt08n8EONgdwOG7oAH33lX1gLqzT3ZcfwOOZ954fwucJ2anlLa1OydrNyoXAYsvyZYOMvpf3Tn2wumEV3pHhYL7oasvsbS3rYw9ZS4PSxOv2OVxPzq5Op4F_USEoCFitgypUYSFsVfcqiQtCLrKkPV5iWMamwkQUhBeUoENjKnkeVQZ5leVVigXHPLMO2xcwaGhSL4GlKhRIbaUykUAhc5lEJo9LYxRGOZZDkD0PdeHLjdtXL251H1e20D3vteW9dgF2yRBGW7pVV3DjQYqkXyLdp5OSAtRkE_6NElu_j1sd6ZbrUP8ka0PItpQ_iOtfjfqulyNNe9k6aEyDyw2NRugpjlNC8H_qw5PMvQw_hKNOCLd84okKM57w4_-Y3Vt4Mr2aXerL8_nFK3hq_9jwmEi-hsH6foMnhMHW-Ru_x74BB70wGA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fingolimod+suppresses+bone+resorption+in+female+patients+with+multiple+sclerosis&rft.jtitle=Journal+of+neuroimmunology&rft.au=Miyazaki%2C+Yusei&rft.au=Niino%2C+Masaaki&rft.au=Kanazawa%2C+Ippei&rft.au=Suzuki%2C+Masako&rft.date=2016-09-15&rft.issn=1872-8421&rft.eissn=1872-8421&rft.volume=298&rft.spage=24&rft_id=info:doi/10.1016%2Fj.jneuroim.2016.06.007&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01655728%2FS0165572816X00070%2Fcov150h.gif |